Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galderma Group AGXSWX:GALD +1.19%14 EV-to-EBITDA is 46.69 as of Jul. 22, 2026, which is 35% above its 10-year median of 34.48. GuruFocus rates XSWX:GALD with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 741 Drug Manufacturers companies, Galderma Group AG ranks worse than 87.31% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Galderma Group AG's enterprise value is CHF42,649 Mil.
Galderma Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF914 Mil. Therefore, Galderma Group AG's EV-to-EBITDA for today is 46.69.
The historical rank and industry rank for Galderma Group AG's EV-to-EBITDA or its related term are showing as below:
XSWX:GALD'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 23.57 Med: 34.48 Max: 48.74
Current: 46.69
During the past 5 years, the highest EV-to-EBITDA of Galderma Group AG was 48.74. The lowest was 23.57. And the median was 34.48.
XSWX:GALD's EV-to-EBITDA is ranked worse than 87.31% of 741
companies
in the Drug Manufacturers industry
Industry Median: 13.24
vs XSWX:GALD: 46.69
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Galderma Group AG (XSWX:GALD) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Galderma Group AG's PE Ratio (TTM) for today is calculated as:
Galderma Group AG's share price for today is CHF175.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galderma Group AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was CHF2.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Galderma Group AG's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:GALD vs ZTS, UTHR, VTRS: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's EV-to-EBITDA falls into.
Galderma Group AG's current Enterprise Value is CHF42,649 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galderma Group AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was CHF914 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (XSWX:GALD) has a EV-to-EBITDA of 46.69 as of Jul. 22, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Galderma Group AG. This is 35% above median its historical median of 34.48. Over the past decade, Galderma Group AG's EV-to-EBITDA has ranged from 23.57 to 48.74. According to the industry distribution chart, Galderma Group AG ranks #647 out of 741 companies in the Drug Manufacturers industry, placing it in the top 87.3%.
Is Galderma Group AG's EV-to-EBITDA too high?
Galderma Group AG's current EV-to-EBITDA of 46.69 is 35% above median its 10-year median of 34.48. Over the past 10 years, this metric has ranged from a low of 23.57 to a high of 48.74. The Drug Manufacturers industry median EV-to-EBITDA is 13.24. Galderma Group AG's value of 46.69 is 252.6% above this industry median. Based on the distribution chart, Galderma Group AG ranks #647 out of 741 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Galderma Group AG has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #647 out of 741 companies for EV-to-EBITDA. This places Galderma Group AG in the lower half of its industry. The industry median EV-to-EBITDA is 13.24. Galderma Group AG's value of 46.69 is 252.6% above this benchmark. Historically, Galderma Group AG's own EV-to-EBITDA has ranged from 23.57 to 48.74 over the past decade. While the company's 10-year median is 34.48 vs. the industry median of 13.24, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.24, based on 741 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current EV-to-EBITDA of 46.69 is 252.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Galderma Group AG. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current EV-to-EBITDA is 46.69, which is 35% above median its own 10-year median of 34.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current EV-to-EBITDA of 46.69. The current EV-to-EBITDA is 46.69, which is 35% above median its 10-year median of 34.48 and 252.6% above the Drug Manufacturers industry median of 13.24. Galderma Group AG's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current EV-to-EBITDA is 46.69 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
14GF Score
Get the complete analysis for XSWX:GALD
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 
